NCT05354349View on ClinicalTrials.gov

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

PHASE1CompletedINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions

Healthy

Interventions

DRUG

PRA023 IV Low Dose

Drug

DRUG

PRA023 SC

Drug

DRUG

Placebo IV

Placebo

DRUG

Placebo SC

Placebo

DRUG

PRA023 IV High Dose

Drug

Trial Locations (1)

90630

Altasciences Clinical LA, Inc., Cypress

All Listed Sponsors

collaborator

Altasciences Company Inc.

INDUSTRY

lead

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY